Making a ‘sex-difference fact’: Ambien dosing at the interface of policy, regulation, women’s health, and biology

The U.S. Food and Drug Administration’s (FDA) 2013 decision to lower recommended Ambien dosing for women has been widely cited as a hallmark example of the importance of sex differences in biomedicine. Using regulatory documents, scientific publications, and media coverage, this article analyzes the...

Full description

Saved in:
Bibliographic Details
Published in:Social studies of science Vol. 53; no. 4; pp. 475 - 494
Main Authors: Zhao, Helen, DiMarco, Marina, Ichikawa, Kelsey, Boulicault, Marion, Perret, Meg, Jillson, Kai, Fair, Alexandra, DeJesus, Kai, Richardson, Sarah S.
Format: Journal Article
Language:English
Published: London, England SAGE Publications 01-08-2023
Sage Publications Ltd
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The U.S. Food and Drug Administration’s (FDA) 2013 decision to lower recommended Ambien dosing for women has been widely cited as a hallmark example of the importance of sex differences in biomedicine. Using regulatory documents, scientific publications, and media coverage, this article analyzes the making of this highly influential and mobile ‘sex-difference fact’. As we show, the FDA’s decision was a contingent outcome of the drug approval process. Attending to how a contested sex-difference fact came to anchor elite women’s health advocacy, this article excavates the role of regulatory processes, advocacy groups, and the media in producing perceptions of scientific agreement while foreclosing ongoing debate, ultimately enabling the stabilization of a binary, biological sex-difference fact and the distancing of this fact from its conditions of construction.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0306-3127
1460-3659
DOI:10.1177/03063127231168371